SAVA
Cassava Sciences Inc
-13.96%
$29.88 - $25.71
Feb 7th 2023 - Mar 21st 2023
Mar, 21, 2023
Data tells me no safety issues, with a possible la... See more
Feb, 25, 2023
Then they dropped the “good” totally “not disappoi... See more
AVXL
Anavex Life Sciences Corporation
-22.55%
$11.75 - $9.10
Feb 7th 2023 - Mar 21st 2023
Mar, 5, 2023
We are excited about the data and plan to submit t... See more
Mar, 3, 2023
$AVXL Australia trial data meets the gold standard.
BCRX
Biocryst Pharmaceuticals Inc.
-23.50%
$10.68 - $8.17
Feb 7th 2023 - Mar 21st 2023
Mar, 3, 2023
$BCRX European stocks rose on Friday as investor... See more
Jan, 12, 2023
#1 Suddenly alot of positive accounts appear, prom... See more
Mar, 21, 2023
Data tells me no safety issues, with a possible large therapeutic window.
Feb, 25, 2023
Then they dropped the “good” totally “not disappointing” data that Remi was so “Thrilled” about.
Feb, 24, 2023
This will go beyond parabolic on good data … literally no shares out there unless they offer new ones … $MDGL $VKTX $SLS $SAVA
Feb, 6, 2023
SAVA data gets analyzed by multiple different labs and shows its cognition improvement in mild AD cases, safe and well-tolerated
Jan, 30, 2023
$SAVA I love not being able to hold $28 off data that will keep it pinned here until 2024.
Jan, 30, 2023
but the data to date would predict continued efficacy that will be nigh on impossible to ignore.
Jan, 30, 2023
Data teasing is very positive. 🚀
Jan, 18, 2023
$SAVA Institutional buying says data is good!! !
Jan, 18, 2023
I’ll keep buying until data comes out…
Jan, 17, 2023
Excited for the next data unveiling….bring it on!
Mar, 5, 2023
We are excited about the data and plan to submit the data for publication and peer reviewed medical journal in the near term.
Mar, 3, 2023
$AVXL Australia trial data meets the gold standard.
Feb, 24, 2023
$AVXL - Alz Topline Data was solid ..
Feb, 14, 2023
Efficacy is likey overwhelming after seeing 👀 data details!
Feb, 14, 2023
$AVXL I am extremely bullish on the data .. the FDA can ask any sorts of questions
Jan, 31, 2023
I'm looking forward to seeing the long term AD data on ANVS and have the feeling it's going to end up being the best in class AD treatment as well.
Jan, 28, 2023
Now DATA met expectations.
Jan, 24, 2023
Also clint said every time Blarcamesine data comes back it looks better and better. .
Jan, 24, 2023
Anavex has significant 4 years of ph2/3 safety data with safety back to 2013 for Blarcamesine .. anavex has full 3 endpoint trial and a placebo .. it's obvious Anavex wins!!
Jan, 22, 2023
So I think the data so far was encouraging,
Mar, 3, 2023
$BCRX European stocks rose on Friday as investors took an optimistic view of a week of data releases that showed economies in Europe and the US were more robust than expected.
Jan, 12, 2023
#1 Suddenly alot of positive accounts appear, promoting the company has solid data, solid sales
Jan, 11, 2023
$BCRX Have strong feeling once 10013 data is out we are going places.
Jan, 9, 2023
P1 data is nice ,
Jan, 9, 2023
The data looks good.
Jan, 9, 2023
$BCRX This preliminary data on BCX10013 is pretty impressive.
Jan, 9, 2023
$BCRX Good 10013 data.
Jan, 9, 2023
10013 data looks good,
Jan, 9, 2023
$BCRX great 10013 data and 320+ projected rev
Jan, 5, 2023
but it also seems like the good choice to do so seeing iptacopan data.